These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 15041109)
1. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L; Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109 [TBL] [Abstract][Full Text] [Related]
2. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Schröder FH; Collette L; de Reijke TM; Whelan P Br J Cancer; 2000 Jan; 82(2):283-90. PubMed ID: 10646878 [TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Pummer K; Lehnert M; Stettner H; Hubmer G Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791 [TBL] [Abstract][Full Text] [Related]
5. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153 [TBL] [Abstract][Full Text] [Related]
6. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535 [TBL] [Abstract][Full Text] [Related]
7. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805 [TBL] [Abstract][Full Text] [Related]
8. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. Studer UE; Whelan P; Albrecht W; Casselman J; de Reijke T; Hauri D; Loidl W; Isorna S; Sundaram SK; Debois M; Collette L J Clin Oncol; 2006 Apr; 24(12):1868-76. PubMed ID: 16622261 [TBL] [Abstract][Full Text] [Related]
9. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate]. Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783 [TBL] [Abstract][Full Text] [Related]
10. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Robinson MR; Smith PH; Richards B; Newling DW; de Pauw M; Sylvester R Eur Urol; 1995; 28(4):273-83. PubMed ID: 8575493 [TBL] [Abstract][Full Text] [Related]
11. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Crook J; Ludgate C; Malone S; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):327-33. PubMed ID: 18707821 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Bolla M Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699 [TBL] [Abstract][Full Text] [Related]
13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106 [TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life among patients with metastatic prostate cancer. Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282 [TBL] [Abstract][Full Text] [Related]
15. Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate? Datta SN; Thomas K; Matthews PN J Urol; 1997 Jul; 158(1):175-7. PubMed ID: 9186348 [TBL] [Abstract][Full Text] [Related]
16. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J; Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. Miyake H; Hara I; Eto H BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202 [TBL] [Abstract][Full Text] [Related]
19. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458 [TBL] [Abstract][Full Text] [Related]
20. Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review. Oosterlinck W; Mast P Acta Urol Belg; 1994 Apr; 62(1):67-71. PubMed ID: 8197932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]